Subscribe To
MNPR / Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today?
MNPR News
By Zacks Investment Research
May 29, 2023
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
After losing some value lately, a hammer chart pattern has been formed for Monopar Therapeutics Inc. (MNPR), indicating that the stock has found suppo more_horizontal
By InvestorPlace
March 28, 2023
Why Is Monopar Therapeutics (MNPR) Stock Down 47% Today?
Monopar Therapeutics (NASDAQ: MNPR ) stock is taking a beating on Tuesday after the company revealed lackluster clinical trial results. These results more_horizontal
By GlobeNewsWire
March 28, 2023
Monopar to Present at the Jefferies Radiopharma Innovation Summit
WILMETTE, Ill., March 28, 2023 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on dev more_horizontal
By Zacks Investment Research
November 18, 2022
Monopar Therapeutics (MNPR) Up On Soft Tissue Sarcoma Study Data
Monopar Therapeutics (MNPR) surges after it reports data from its ongoing phase Ib dose escalation study evaluating camsirubicin for treating soft-tis more_horizontal